ArticleBMC cancer2017
Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- A complete pathological response to preoperative chemotherapy in a male patient with primary neuroendocrine breast cancer: a case report.Journal of medical case reports · 2026Article
- Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas.Oncogenesis · 2022Article
- Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.Human pathology · 2022Article
- A high-quality model for predicting the prognosis of breast neuroendocrine carcinoma to help clinicians decide on appropriate treatment methods: A population-based analysis.Translational oncology · 2022Article
- Clinical and genomic analyses of neuroendocrine neoplasms of the breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis.Geburtshilfe und Frauenheilkunde · 2022Article
- Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types.Frontiers in medicine · 2022Article
- Breast cancer with neuroendocrine differentiation: an update based on the latest WHO classification.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Rare Breast Cancer Subtypes.Current oncology reports · 2021Review
- Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review.Sisli Etfal Hastanesi tip bulteni · 2021Article
- Primary neuroendocrine carcinoma of the breast: a rare presentation and review of the literature.Intractable & rare diseases research · 2020Article
- The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.The oncologist · 2020Article
- Neuroendocrine breast carcinoma: a rare but challenging entity.Medical oncology (Northwood, London, England) · 2020Review
- Neuroendocrine Cancer of the Breast: A Rare Entity.Journal of clinical medicine · 2020Review
- Neuroendocrine Carcinomas of the Canine Mammary Gland: Histopathological and Immunohistochemical Characteristics.Frontiers in veterinary science · 2020Article
- Rare epithelial breast cancer: surgery and adjuvant therapy.Translational cancer research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms, WHO classification of which has recently been revised. There are very limited data available about the clinical behaviour and treatment options of NEBC.
methodsWe collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007-2015. There were 43 NEBC cases during the period.
resultsThe incidence of NEBC from all breast cancers varied from 0.1% in Helsinki to 1.3% in Oulu. The mean tumor size was 2.2 cm and 23 patients (55.8%) had no lymph node metastases when diagnosed. In total, 4 patients (9.3%) had distant metastases at the time of diagnosis. High estrogen receptor (ER) expression was observed in 41 (97.7%) patients. When non-metastatic NEBC were compared to a prospective set of ductal carcinomas (n = 506), NEBC were more often HER2 negative (p = 0.046), ER positive (p = 0.0062) and the NEBC patients were older (p < 0.0005) than patients with ductal carcinomas. Plasma chromogranin A correlated only to higher age at diagnosis (p = 0.0028). Relapse-free survival (p = 0.0013), disease-free survival (p = 0.024) and overall survival (p = 0.0028) favoured ductal carcinomas compared to NEBC, while no difference was observed in distant disease-free survival or in breast cancer-specific survival.
conclusionsThere is remarkable variation in the incidence of NEBC in Finland, which is likely to be explained by differences in the use of neuroendocrine marker immunostainings. Poor local control and worse overall survival may be linked to the more aggressive biology of the disease, despite its association with apparently indolent prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.